Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Variability in epilepsy polygenic risk prediction across Taiwanese population and clinical cohorts.

Epilepsia·2026
Same author

Effectiveness of preoperative pulmonary rehabilitation in patients with lung cancer combined with moderate to severe COPD: study protocol for a randomized controlled trial.

Respiratory medicine·2026
Same author

Clinical spectrum of pediatric-onset Erdheim-Chester disease: insights from a single-center case series.

Frontiers in pediatrics·2026
Same author

Therapeutic effects of 40 Hz light stimulation on clinical and pathological features of Alzheimer's disease.

Dialogues in clinical neuroscience·2026
Same author

Development and Validation of a Machine Learning-Based Dementia Screening Tool: The Six-Question Dementia Screening Test.

American journal of Alzheimer's disease and other dementias·2026
Same author

Using Plasma Amyloid Beta Oligomer to Screen in Alzheimer's Disease: A Pilot Study.

International journal of molecular sciences·2026
Same journal

Patient-derived forebrain cortical organoids reveal biphasic tau-MAP6-microtubule axis dysfunction in tauopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Genetic architecture of the limbic white matter microstructure in aging and Alzheimer's Disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Greater choroid plexus volume is linked to poor sleep, neurodegeneration, and cognitive deficits in older adults: Evidence from the IGNITE Study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Plasma-based neurobiological protein biomarkers as predictors of dementia progression: Insights from longitudinal aging study in India - Diagnostic assessment of dementia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Neuropathology-specific language features in primary progressive aphasia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Dementia blood biomarkers in the context of post-stroke cognitive outcomes: Systematic review and evidence synthesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Pin-Chieh Hsu1, Jia-Ying Yang2, Yuan-Han Yang3,4,5,6

  • 1Kaohsiung Medical University, Kaohsiung, Kaohsiung, Taiwan.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
PubMed
Summary
This summary is machine-generated.

Higher levels of plasma amyloid-beta oligomers (AβO) are significantly linked to Alzheimer's disease (AD). This finding suggests AβO could serve as a potential blood biomarker for AD screening.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neuroscience
  • Biomarker Discovery
  • Alzheimer's Disease Research

Background:

  • Plasma amyloid-beta oligomers (AβO), toxic forms of amyloid-beta, are implicated in Alzheimer's disease (AD) development and progression.
  • Previous research indicates a critical role for AβO in the pathogenesis of AD.

Purpose of the Study:

  • To investigate plasma amyloid-beta oligomers (AβO) and related biomarkers in individuals with Alzheimer's disease (AD) compared to cognitively normal controls.
  • To clarify the association between plasma AβO levels and AD diagnosis.

Main Methods:

  • A case-control study involving 16 AD patients and 16 cognitively normal controls (NCs).
  • Plasma biomarkers including Aβ oligomers (AβO), Aβ1-40, and Aβ1-42 were measured using ELISA kits.
  • Demographic and clinical data (age, sex, education, APOE ε4, CDR, MMSE) were analyzed; Spearman's correlation was used to assess relationships.

Main Results:

  • Significantly higher mean plasma concentrations of Aβ1-40, Aβ1-42, and AβO were observed in AD patients compared to NCs.
  • Plasma Aβ1-40 (67.4 pg/mL vs 21.4 pg/mL, p < 0.001) and AβO (157.1 pg/mL vs 107.3 pg/mL, p = 0.003) were significantly elevated in AD.
  • Aβ1-40 and the Aβ1-42/1-40 ratio showed significant correlations with AβO levels (p=0.003 and p=0.002, respectively).

Conclusions:

  • Elevated plasma concentrations of amyloid-beta oligomers (AβO) are significantly associated with Alzheimer's disease (AD).
  • Plasma AβO shows potential as a screening biomarker for AD.
  • Further research with larger cohorts is warranted to confirm these findings and explore the diagnostic utility of AβO.